NICE backs Celgene’s Otezla for psoriatic arthritis

pharmafile | October 12, 2016 | News story | Research and Development, Sales and Marketing Celgene, NICE, otezla 

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic arthritis in England and Wales.

The news follows the drug’s recommendation for use in the treatment of severe psoriasis in August. It was originally rejected in November last year despite its counterpart the Scottish Medicines Consortium’s decision to approve it.

The drug now provides patients with an oral pill treatment option as opposed to the many available injectable alternatives. NICE has recommended it for use alone or together with disease-modifying antirheumatic drugs (DMARDs) in adults who have not previously responded to them, despite calling it a “less-effective treatment” than its alternatives, on the condition that drug is made available via a patient access scheme in order to make it cost-effective.

Advertisement

Otezla is listed on the NHS as costing £265.18 for a 14-day treatment initiation pack (4×10mg, 4×20mg and 19×30mg) and £550.00 for a 28-day pack (56×30mg). Analysts expect the drug to generate $1.3 billion by 2018, while the company has set its sights on an even higher $2 billion.

Matt Fellows

Related Content

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

The Gateway to Local Adoption Series

Latest content